NADAC acquisition cost data for TRAVOPROST 0.004% EYE DROP. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378965150 | $22.25 | 2022-12-21 | Rx |
| 00781618575 | $22.25 | 2022-12-21 | Rx |
| 42571013021 | $22.25 | 2022-12-21 | Rx |
| 60505059301 | $22.25 | 2022-12-21 | Rx |
| 00378965132 | $26.10 | 2022-12-21 | Rx |
| 00781618556 | $26.10 | 2022-12-21 | Rx |
| 42571013027 | $26.10 | 2022-12-21 | Rx |
| 60505059304 | $26.10 | 2022-12-21 | Rx |
| 00378965150 | $22.25 | 2022-12-21 | Rx |
| 00781618575 | $22.25 | 2022-12-21 | Rx |
Generic: Travoprost | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $864.1K | 3,433 | 3,432 | $56.50 |
| 2020 | $154.1M | 660,013 | 184,367 | $51.90 |
| 2021 | $144.2M | 615,678 | 157,869 | $49.98 |
| 2022 | $129.3M | 560,717 | 137,795 | $48.06 |
| 2023 | $114.1M | 503,400 | 123,672 | $45.63 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $10.4M | 47,461 | 12,096 |
| New York | $10.3M | 40,799 | 10,473 |
| Florida | $10.0M | 45,846 | 11,018 |
| Texas | $9.8M | 39,427 | 10,265 |
| Pennsylvania | $7.0M | 30,182 | 7,307 |
| Illinois | $4.3M | 18,153 | 4,764 |
| New Jersey | $4.1M | 17,781 | 4,601 |
| North Carolina | $3.8M | 18,144 | 4,338 |
| Georgia | $3.8M | 16,530 | 4,289 |
| Ohio | $2.8M | 12,627 | 3,243 |
| Connecticut | $2.7M | 9,700 | 2,574 |
| Michigan | $2.6M | 11,984 | 3,209 |
| Virginia | $2.5M | 10,404 | 2,810 |
| Tennessee | $2.4M | 10,207 | 2,782 |
| Maryland | $2.3M | 8,185 | 2,472 |
| Arizona | $2.3M | 9,421 | 2,516 |
| Indiana | $2.1M | 8,887 | 2,432 |
| Wisconsin | $2.0M | 10,447 | 2,513 |
| Alabama | $2.0M | 8,788 | 2,134 |
| Missouri | $1.9M | 9,524 | 2,254 |
| South Carolina | $1.9M | 8,387 | 2,229 |
| Massachusetts | $1.9M | 7,793 | 2,123 |
| Washington | $1.8M | 8,339 | 2,209 |
| Minnesota | $1.7M | 7,576 | 1,810 |
| Louisiana | $1.6M | 8,252 | 2,015 |
| Oklahoma | $1.3M | 5,917 | 1,465 |
| Puerto Rico | $1.2M | 8,417 | 1,353 |
| Kentucky | $1.2M | 5,436 | 1,426 |
| Colorado | $1.1M | 4,640 | 1,202 |
| Mississippi | $981.0K | 5,368 | 1,294 |
| Oregon | $936.2K | 4,859 | 1,269 |
| Arkansas | $885.6K | 4,539 | 1,008 |
| Iowa | $839.9K | 4,143 | 980 |
| Maine | $768.6K | 2,890 | 834 |
| Kansas | $737.8K | 4,089 | 897 |
| West Virginia | $720.1K | 3,444 | 843 |
| New Hampshire | $579.2K | 2,421 | 635 |
| New Mexico | $520.6K | 2,350 | 594 |
| Delaware | $494.1K | 1,769 | 506 |
| Rhode Island | $484.7K | 2,073 | 478 |
| Nevada | $474.9K | 2,094 | 601 |
| Nebraska | $441.6K | 2,342 | 536 |
| Utah | $376.0K | 1,686 | 440 |
| District of Columbia | $327.9K | 1,034 | 339 |
| Hawaii | $303.7K | 1,079 | 333 |
| Idaho | $294.0K | 1,495 | 376 |
| Alaska | $255.2K | 1,142 | 310 |
| Vermont | $240.4K | 968 | 248 |
| North Dakota | $213.8K | 1,226 | 259 |
| Montana | $161.6K | 795 | 211 |
| South Dakota | $160.0K | 894 | 202 |
| Virgin Islands | $140.6K | 760 | 170 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.